The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes

• DOI: 10.2337/dc09-2042
• Publication Date: 2010-03-24T02:14:57Z
• Authors: Elbert S. Huang; Michael O'Grady; Anirban Basu; Aaron Winn; Priya John; Joyce Lee; David Meltzer; Craig Kollman; Lori Laffel; William Tamborlane; Stuart Weinzimer; Tim Wysocki
• Keywords: Blood Glucose Self-Monitoring

OBJECTIVE Continuous glucose monitoring (CGM) has been found to improve control in type 1 diabetic patients. We estimated the cost-effectiveness of CGM versus standard diabetes. RESEARCH DESIGN AND METHODS This societal analysis (CEA) was conducted trial populations which produced a significant glycemic benefit (A1C ≥7.0% cohort adults aged ≥25 years and A1C <7.0% all ages). Trial data were integrated into simulation model diabetes complications. The main outcome cost per quality-adjusted life-year (QALY) gained. RESULTS During trials, patients experienced an immediate quality-of-life cohort: 0.70 life-weeks [QALWs], P = 0.49; 1.39 QALWs, 0.04) improved control. In long-term, CEA for cohort, projected reduce lifetime probability microvascular complications; average gain QALYs 0.60. incremental ratio (ICER) $98,679/QALY (95% CI −60,000 [fourth quadrant] −87,000 [second quadrant]). For 1.11. ICER $78,943/QALY (15,000 [first −291,000 If had limited long-term effects control, would exceed $700,000/QALY. test strip use two day with long term significantly. CONCLUSIONS Long-term projections indicate that is cost-effective among at $100,000/QALY threshold, although considerable uncertainty surrounds these estimates.